Vai al contenuto principale della pagina
Autore: | Alvarez Ricardo H |
Titolo: | Handbook of HER2-targeted agents in breast cancer / / by Ricardo H Alvarez, Javier Cortés, Leticia Mattos-Arruda, Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni, Nadia Harbeck, Martine Piccart, Stefania Zambelli, Dimitrios Zardavas |
Pubblicazione: | Tarporley : , : Springer Healthcare Ltd. : , : Imprint : Springer Healthcare, , 2013 |
Edizione: | 1st ed. 2013. |
Descrizione fisica: | 1 online resource (107 p.) |
Disciplina: | 616.99449 |
Soggetto topico: | Oncology |
Primary care (Medicine) | |
General practice (Medicine) | |
Internal medicine | |
Pharmacotherapy | |
Oncology | |
Primary Care Medicine | |
General Practice / Family Medicine | |
Internal Medicine | |
Persona (resp. second.): | CortésJavier |
Mattos-ArrudaLeticia | |
FalzonMary | |
FasoloAngelica | |
GandyMichael | |
GianniLuca | |
HarbeckNadia | |
PiccartMartine | |
ZambelliStefania | |
ZardavasDimitrios | |
Note generali: | Description based upon print version of record. |
Nota di bibliografia: | Includes bibliographical references. |
Nota di contenuto: | Introduction and background biology -- HER2 testing -- HER2-positive breast cancer: adjuvant and neoadjuvant therapy -- HER2-positive metastatic breast cancer: first-line treatment -- HER2-positive metastatic breast cancer: second-line treatment -- Emerging targeted agents for HER2-positive breast cancer. |
Sommario/riassunto: | Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings. |
Titolo autorizzato: | Handbook of HER2-targeted agents in breast cancer |
ISBN: | 1-907673-94-6 |
Formato: | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione: | Inglese |
Record Nr.: | 9910438014903321 |
Lo trovi qui: | Univ. Federico II |
Opac: | Controlla la disponibilità qui |